AU2020371040B2 - Means and methods for treating subjects with HER2 and HER3 positive cancer - Google Patents

Means and methods for treating subjects with HER2 and HER3 positive cancer

Info

Publication number
AU2020371040B2
AU2020371040B2 AU2020371040A AU2020371040A AU2020371040B2 AU 2020371040 B2 AU2020371040 B2 AU 2020371040B2 AU 2020371040 A AU2020371040 A AU 2020371040A AU 2020371040 A AU2020371040 A AU 2020371040A AU 2020371040 B2 AU2020371040 B2 AU 2020371040B2
Authority
AU
Australia
Prior art keywords
erbb
sequence
cdr2
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020371040A
Other languages
English (en)
Other versions
AU2020371040A1 (en
Inventor
Leonardo Andres SIRULNIK
Ernesto Isaac WASSERMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merus BV
Original Assignee
Merus BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus BV filed Critical Merus BV
Publication of AU2020371040A1 publication Critical patent/AU2020371040A1/en
Application granted granted Critical
Publication of AU2020371040B2 publication Critical patent/AU2020371040B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020371040A 2019-10-24 2020-10-23 Means and methods for treating subjects with HER2 and HER3 positive cancer Active AU2020371040B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2024097 2019-10-24
NL2024097 2019-10-24
PCT/NL2020/050656 WO2021080428A1 (en) 2019-10-24 2020-10-23 Means and methods for treating subjects with her2 and her3 positive cancer

Publications (2)

Publication Number Publication Date
AU2020371040A1 AU2020371040A1 (en) 2022-05-12
AU2020371040B2 true AU2020371040B2 (en) 2025-10-09

Family

ID=68807359

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020371040A Active AU2020371040B2 (en) 2019-10-24 2020-10-23 Means and methods for treating subjects with HER2 and HER3 positive cancer

Country Status (9)

Country Link
US (1) US20220372166A1 (enExample)
EP (1) EP4048702A1 (enExample)
JP (2) JP7532514B2 (enExample)
KR (1) KR20220103954A (enExample)
CN (2) CN116327919A (enExample)
AU (1) AU2020371040B2 (enExample)
CA (1) CA3158609A1 (enExample)
TW (1) TWI873210B (enExample)
WO (1) WO2021080428A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600411A1 (en) * 2017-03-31 2020-02-05 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182422A1 (en) * 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013022887A2 (pt) * 2011-03-15 2016-12-06 Merrimack Pharmaceuticals Inc superação de resistência a inibidores de via de erbb
CN120383672A (zh) 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
IL301147A (en) * 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
EP3110846B1 (en) * 2014-02-28 2020-08-19 Merus N.V. Antibodies that bind egfr and erbb3
US20210206875A1 (en) * 2017-03-31 2021-07-08 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
EA201992522A1 (ru) * 2017-05-17 2020-04-22 Мерус Н.В. КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
WO2022098233A1 (en) * 2020-11-04 2022-05-12 Merus N.V. Means and methods for treating subjects with erbb3 mutation positive cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182422A1 (en) * 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. M. SCHRAM ET AL:ANNALS OF ONCOLOGY., vol. 30, no. Supplement 5, 1 October 2019 (2019-10-01), NL, pages v317, XP055765897, ISSN: 0923-7534, DOI: 10.1093/annonc/mdz247 *
ANONYMOUS: NCT04100694, 24 September 2019 (2019-09-24), XP002801682, Retrieved from the Internet [retrieved on 20210118] *
ANONYMOUS: Study NCT02912949, 23 October 2019, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history/NCT02912949?V_6=View#StudyPageTop [retrieved on 2021-01-18] *

Also Published As

Publication number Publication date
AU2020371040A1 (en) 2022-05-12
JP7678175B2 (ja) 2025-05-15
EP4048702A1 (en) 2022-08-31
CA3158609A1 (en) 2021-04-29
CN116327919A (zh) 2023-06-27
KR20220103954A (ko) 2022-07-25
JP2024071393A (ja) 2024-05-24
JP2022553104A (ja) 2022-12-21
JP7532514B2 (ja) 2024-08-13
WO2021080428A1 (en) 2021-04-29
TWI873210B (zh) 2025-02-21
TW202130664A (zh) 2021-08-16
US20220372166A1 (en) 2022-11-24
CN114761436A (zh) 2022-07-15

Similar Documents

Publication Publication Date Title
US12247078B2 (en) ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US20240026029A1 (en) Means and methods for treating subjects with erbb3 mutation positive cancer
US20200291130A1 (en) Antibodies for the treatment of erbb-2/erbb-3 positive tumors
JP7678175B2 (ja) Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法
CN111773385B (zh) ErbB2抗体与Saracatinib联合应用在制备治疗乳腺癌药物中的应用
CN118055949A (zh) 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症
WO2025188180A1 (en) Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression
HK40021172A (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene